XERIS BIOPHARMA HOLDINGS, INC. Proceeds from Issuance of Warrants
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Proceeds from Issuance of Warrants of $7.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for the quarter ending 2026-06-30 was $600.00K.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for the quarter ending 2026-03-31 was $7.33M.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for the quarter ending 2025-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for the quarter ending 2025-09-30 was $9.17M.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for fiscal 2025 was $9.17M.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for fiscal 2024 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of warrants for fiscal 2023 was $0.00.
| Period end | Proceeds from Issuance of Warrants 1 month | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $600.00K 10-Q · filed 2026-08-06 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.93M 10-Q · filed 2026-08-06 | $7.93M derived: sum of 3 quarters · filed 2026-08-06 | $17.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.33M 10-Q · filed 2026-05-07 | $7.33M derived: sum of 2 quarters · filed 2026-05-07 | $16.50M derived: sum of 3 quarters · filed 2026-05-07 | $16.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-01-31 | $7.30M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.17M derived: sum of 2 quarters · filed 2026-03-02 | $9.17M derived: sum of 3 quarters · filed 2026-08-06 | $9.17M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $9.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.17M derived: sum of 2 quarters · filed 2026-08-06 | $9.17M 10-Q · filed 2025-11-06 | $9.17M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |